PregLem, acquired by the Richter Group in 2010 for 445 million Swiss Francs, is a Swiss-based specialty Biopharma company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine. PregLem’s activities focus on developing therapies for gynecologic conditions with significant unmet needs and that have a severe impact on the patient’s quality of life: uterine fibroids, endometriosis, infertility through ovarian reserve modulation, and post-surgical adhesions.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.